Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia

NeuroImage: Clinical

Volumn 7, Issue , 2015, Pages 187-194

  Cerami, Chiara ^a,b   Della Rosa, Pasquale Anthony ^c   Magnani, Giuseppe ^b   Santangelo, Roberto ^b   Marcone, Alessandra ^b   Cappa, Stefano F ^d   Perani, Daniela ^a,b,c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^d SCUOLA UNIVERSITARIA SUPERIORE IUSS PAVIA   (Italy)

Author keywords

Alzheimer's disease; Cognitive; Dementia diagnosis; Impairment 18F FDG; Mild; PET imaging

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRAIN MAPPING; BRAIN METABOLISM; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HUMAN; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROTEIN CEREBROSPINAL FLUID LEVEL; STATISTICAL PARAMETERS; STATISTICAL PARAMETRIC MAPPING; VERY ELDERLY; VOXEL BASED MORPHOMETRY; BRAIN; COMPUTER ASSISTED DIAGNOSIS; DEMENTIA; METABOLISM; PROCEDURES; SCINTISCANNING;

AGED; BRAIN; BRAIN MAPPING; DEMENTIA; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RADIOPHARMACEUTICALS;

EID: 84919708754     PISSN: None     EISSN: 22131582     Source Type: Journal    
DOI: 10.1016/j.nicl.2014.12.004     Document Type: Article

References (73)

1. Alberici A.; Geroldi C.; Cotelli M.; Adorni A.; Calabria M.; and Rossi G. The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease Neurol. Sci. 28 2 2007 80 86 10.1007/s10072-007-0791-3 17464470
2. Albert M.S.; DeKosky S.T.; Dickson D.; Dubois B.; Feldman H.H.; and Fox N.C. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 3 2011 270 279 10.1016/j.jalz.2011.03.008 21514249
3. Anchisi D.; Borroni B.; Franceschi M.; Kerrouche N.; Kalbe E.; and Beuthien-Beumann B. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease Arch. Neurol. 62 11 2005 1728 1733 10.1001/archneur.62.11.1728 16286547
4. Armstrong M.J.; Litvan I.; Lang A.E.; Bak T.H.; Bhatia K.P.; and Borroni B. Criteria for the diagnosis of corticobasal degeneration Neurology 80 5 2013 496 503 10.1212/WNL.0b013e31827f0fd1 23359374
5. Bateman R.J.; Xiong C.; Benzinger T.L.; Fagan A.M.; Goate A.; and Fox N.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N. Engl. J. Med. 367 9 2012 795 804 10.1056/NEJMoa1202753 22784036
6. 18F]FDG and MR imaging in patients with mild cognitive impairment Eur. J. Nucl. Med. Mol. Imaging 40 10 2013 1567 1572 10.1007/s00259-013-2478-8 23801168
7. Busse A.; Hensel A.; Gühne U.; Angermeyer M.C.; and Riedel-Heller S.G. Mild cognitive impairment: long-term course of four clinical subtypes Neurology 67 12 2006 2176 2185 10.1212/01.wnl.0000249117.23318.e1 17190940
8. Cerami C.; Crespi C.; Della Rosa P.A.; Dodich A.; Marcone A.; and Magnani G. Brain changes within the visuo-spatial attentional network in posterior cortical atrophy J. Alzheimers Dis. 43 2 2015 385 395 10.3233/JAD-141275 25114070
9. Chételat G.; Eustache F.; Viader F.; De La Sayette V.; Pélerin A.; and Mézenge F. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment Neurocase 11 1 2005 14 25 10.1080/13554790490896938 15804920
10. Crutch S.J.; Lehmann M.; Schott J.M.; Rabinovici G.D.; Rossor M.N.; and Fox N.C. Posterior cortical atrophy Lancet Neurol. 11 2 2012 170 178 10.1016/S1474-4422(11)70289-7 22265212
11. Cummings J.L.; Mega M.; Gray K.; Rosenberg-Thompson S.; Carusi D.A.; and Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia Neurology 44 12 1994 2308 2314 10.1212/WNL.44.12.2308 7991117
12. De Renzi E.; and Vignolo L.A. The token test: a sensitive test to detect receptive disturbances in aphasics Brain J. Neurol. 85 1962 665 678 10.1093/brain/85.4.665 14026018
13. Della Rosa P.A.; Cerami C.; Gallivanone F.; Prestia A.; Caroli A.; Castiglioni I.; and Gilardi M.C. A standardized [(18)F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia Neuroinformatics 12 4 2014 575 593 10.1007/s12021-014-9235-4 24952892
14. Dubois B.; Feldman H.H.; Jacova C.; Cummings J.L.; Dekosky S.T.; and Barberger-Gateau P. Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol. 9 11 2010 1118 1127 10.1016/S1474-4422(10)70223-4 20934914
15. Dubois B.; Feldman H.H.; Jacova C.; Hampel H.; Molinuevo J.L.; and Blennow K. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol. 13 6 2014 614 629 10.1016/S1474-4422(14)70090-0 24849862
16. Dukart J.; Mueller K.; Villringer A.; Kherif F.; Draganski B.; and Frackowiak R. Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease Neuroimage Clin. 3 2013 84 94 10.1016/j.nicl.2013.07.005 24179852
17. Ewers M.; Brendel M.; Rizk-Jackson A.; Rominger A.; Bartenstein P.; and Schuff N. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects Neuroimage Clin. 4 2014 45 52 10.1016/j.nicl.2013.10.018 24286024
18. Fischer P.; Jungwirth S.; Zehetmayer S.; Weissgram S.; Hoenigschnabl S.; and Gelpi E. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia Neurol. 68 4 2007 288 291 10.1212/01.wnl.0000252358.03285.9d 17242334
19. Fouquet M.; Desgranges B.; Landeau B.; Duchesnay E.; Mézenge F.; and de la Sayette V. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease Brain 132 8 2009 2058 2067 10.1093/brain/awp132 19477964
20. Franceschi M.; Anchisi D.; Pelati O.; Zuffi M.; Matarrese M.; and Moresco R.M. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration Ann. Neurol. 57 2 2005 216 225 10.1002/ana.20365 15668960
21. F. Gallivanone, P.A. Della Rosa, D. Perani, M.G. Gilardi, and I. Castiglioni The impact of different 18FDG PET healthy subject scans for comparison with single patient in SPM analysis Q J Nucl Med Mol Imaging 2014 [Epub ahead of print]
22. Galluzzi S.; Geroldi C.; Amicucci G.; Bocchio-Chiavetto L.; Bonetti M.; and Bonvicini C. Supporting evidence for using biomarkers in the diagnosis of MCI due to AD J. Neurol. 260 2 2013 640 650 10.1007/s00415-012-6694-0 23070466
23. Gamboz N.; Coluccia E.; Iavarone A.; and Brandimonte M.A. Normative data for the pyramids and Palm trees test in the elderly Italian population Neurol. Sci. 30 6 2009 453 458 10.1007/s10072-009-0130-y 19768374
24. Ganguli M.; Snitz B.E.; Saxton J.A.; Chang C.C.; Lee C.W.; and Vander Bilt J. Outcomes of mild cognitive impairment by definition: a population study Arch. Neurol. 68 6 2011 761 767 10.1001/archneurol.2011.101 21670400
25. Garibotto V.; Borroni B.; Kalbe E.; Herholz K.; Salmon E.; and Holtoff V. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence Neurology 71 17 2008 1342 1349 10.1212/01.wnl.0000327670.62378.c0 18936426
26. Gorno-Tempini M.L.; Hillis A.E.; Weintraub S.; Kertesz A.; Mendez M.; and Cappa S.F. Classification of primary progressive aphasia and its variants Neurology 76 11 2011 1006 1014 10.1212/WNL.0b013e31821103e6 21325651
27. Han J.W.; Kim T.H.; Lee S.B.; Park J.H.; Lee J.J.; and Huh Y. Predictive validity and diagnostic stability of mild cognitive impairment subtypes Alzheimers Dement. 8 6 2012 553 559 10.1016/j.jalz.2011.08.007 23102125
28. Hatashita S.; and Yamasaki H. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction PLOS One 8 6 2013 e66877 10.1371/journal.pone.0066877 23799136
29. Herholz K. Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease Expert Rev. Neurother. 10 11 2010 1667 1673 10.1586/ern.10.136 20977325
30. Herholz K.; Salmon E.; Perani D.; Baron J.C.; Holthoff V.; and Frölich L. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET Neuroimage 17 1 2002 302 316 10.1006/nimg.2002.1208 12482085
31. Jack C.R. Jr, Albert M.S.; Knopman D.S.; McKhann G.M.; Sperling R.A.; and Carrillo M.C. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 3 2011 257 262 10.1016/j.jalz.2011.03.004 21514247
32. Jack C.R. Jr, Wiste H.J.; Weigand S.D.; Knopman D.S.; Lowe V.; and Vemuri P. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity Neurology 81 2013 1732 1740 10.1212/01.wnl.0000435556.21319.e4 24132377
33. Juh R.; Pae C.U.; Kim T.S.; Lee C.U.; Choe B.; and Suh T. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis Neurosci. Lett. 383 1-2 2005 22 27 10.1016/j.neulet.2005.03.057 15936506
34. Kawashima S.; Ito K.; Kato T. SEAD-J Study Group Inclusion criteria provide heterogeneity in baseline profiles of patients with mild cognitive impairment: comparison of two prospective cohort studies BMJ Open 2 2 2012 e000773 10.1136/bmjopen-2011-000773 22535791
35. Kertesz A.; Davidson W.; and Fox H. Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia Can. J. Neurol. Sci. 24 1 1997 29 36 9043744
36. Klunk W.E.; and Perani D. Amyloid and neurodegeneration: converging and diverging paths Neurology 81 2013 1728 1729 10.1212/01.wnl.0000435568.38352.2e 24132372
37. Lezak M. Valutazione Neuropsicologica 2000 Edra Oregon Health Sciences University
38. Luzzatti C.; Willmes K.; De-Bleser R.; Bianchi A.; Chiesa G.; and De-Tanti A. New normative data for the Italian version of the Aachen aphasia test Arch. Psicol. Neurol. Psichiatr. 55 6 1994 1086 1131
39. Marra C.; Villa G.; Quaranta D.; Valenza A.; Vita M.G.; and Gainotti G. Probable Alzheimer's disease patients presenting as "focal temporal lobe dysfunction" show a slow rate of cognitive decline J. Int. Neuropsychol. Soc. 18 1 2012 144 150 10.1017/S1355617711001287 22114843
40. McKeith I.G.; Dickson D.W.; Lowe J.; Emre M.; O'Brien J.T.; and Feldman H. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 65 12 2005 1863 1872 10.1212/01.wnl.0000187889.17253.b1 16237129
41. McKhann G.M.; Knopman D.S.; Chertkow H.; Hyman B.T.; Jack C.R. Jr, and Kawas C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 3 2011 263 269 10.1016/j.jalz.2011.03.005 21514250
42. Miceli, G.; Laudanna, A.; Burani, C.; Capasso, R. Batteria per l'analisi dei Deficit Afasici (BADA). Technical Report, Roma (1994). Università Cattolica del Sacro Cuore, Policlinico Gemelli, Cepsag.
43. Minoshima S.; Giordani B.; Berent S.; Frey K.A.; Foster N.L.; and Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease Ann. Neurol. 42 1 1997 85 94 10.1002/ana.410420114 9225689
44. Mitchell A.J.; and Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies Acta Psychiatr. Scand. 119 4 2009 252 265 10.1111/j.1600-0447.2008.01326.x 19236314
45. Morbelli S.; Drzezga A.; Perneczky R.; Frisoni G.B.; Caroli A.; and van Berckel B.N. Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project Neurobiol. Aging 33 11 2012 2533 2550 10.1016/j.neurobiolaging.2012.01.005 22365486
46. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD Eur. J. Nucl. Med. Mol. Imaging 32 4 2005 486 510 10.1007/s00259-005-1762-7 15747152
47. Mosconi L.; Murray J.; Tsui W.H.; Li Y.; Spector N.; and Goldowsky A. Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD Neurology 82 9 2014 752 760 10.1212/WNL.0000000000000181 24523481
48. Mosconi L.; Tsui W.H.; Herholz K.; Pupi A.; Drzezga A.; and Lucignani G. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias J. Nucl. Med. 49 3 2008 390 398 10.2967/jnumed.107.045385 18287270
49. Ossenkoppele R.; Prins N.D.; Pijnenburg Y.A.; Lemstra A.W.; van der Flier W.M.; and Adriaanse S.F. Impact of molecular imaging on the diagnostic process in a memory clinic Alzheimers Dement. 9 4 2013 414 421 10.1016/j.jalz.2012.07.003 23164552
50. Pagani M.; Dessi B.; Morbelli S.; Brugnolo A.; Salmaso D.; and Piccini A. MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings Curr. Alzheimer Res. 7 4 2010 287 294 10.2174/156720510791162368 19939228
51. Patterson J.C.; Lilien D.L.; Takalkar A.; and Pinkston J.B. Early detection of brain pathology suggestive of early AD using objective evaluation of FDG-PET scans Int. J. Alzheimers Dis. 2011 2010 946590 10.4061/2011/946590 20885966
52. Perani D. Functional neuroimaging of cognition Handbook of Clinical Neurology 88 2008 61 111
53. Perani D. FDG PET and cognitive symptoms of dementia Clinical and Translational Imaging 1 4 2013 247 260 10.1007/s40336-013-0029-8
54. D. Perani, P.A. Della Rosa, C. Cerami, F. Gallivanone, F. Fallanca, and E.G. Vanoli Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting Neuroimage Clin. 6 2014 445 454 10.1016/j.nicl.2014.10.009 eCollection 2014
55. Petersen R.C.; Roberts R.O.; Knopman D.S.; Boeve B.F.; Geda Y.E.; and Ivnik R.J. Mild cognitive impairment: ten years later Arch. Neurol. 66 12 2009 1447 1455 10.1001/archneurol.2009.266 20008648
56. Prestia A.; Caroli A.; van der Flier W.M.; Ossenkoppele R.; Van Berckel B.; and Barkhof F. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease Neurology 80 11 2013 1048 1056 10.1212/WNL.0b013e3182872830 23390179
57. Rabinovici G.D.; Rosen H.J.; Alkalay A.; Kornak J.; Furst A.J.; and Agarwal N. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD Neurol. 77 23 2011 2034 2042 10.1212/WNL.0b013e31823b9c5e 22131541
58. Rascovsky K.; Hodges J.R.; Knopman D.; Mendez M.F.; Kramer J.H.; and Neuhaus J. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia Brain 134 9 2011 2456 2477 10.1093/brain/awr179 21810890
59. Ridgway G.R.; Omar R.; Ourselin S.; Hill D.L.; Warren J.D.; and Fox N.C. Issues with threshold masking in voxel-based morphometry of atrophied brains Neuroimage 44 1 2009 99 111 10.1016/j.neuroimage.2008.08.045 18848632
60. Salmon E.; Garraux G.; Delbeuck X.; Collette F.; Kalbe E.; and Zuendorf G. Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia Neuroimage 20 1 2003 435 440 10.1016/S1053-8119(03)00346-X 14527604
61. Sánchez-Juan P.; Ghosh P.M.; Hagen J.; Gesierich B.; Henry M.; and Grinberg L.T. Practical utility of amyloid and FDG-PET in an academic dementia center Neurology 82 3 2014 230 238 10.1212/WNL.0000000000000032 24353340
62. Schroeter M.L.; Stein T.; Maslowski N.; and Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients Neuroimage 47 4 2009 1196 1206 10.1016/j.neuroimage.2009.05.037 19463961
63. 18F]FDG PET: a clinical validation of statistical parametric mapping Neuroimage 9 1999 63 80 10.1006/nimg.1998.0381 9918728
64. Silverman D.H.; Mosconi L.; Ercoli L.; Chen W.; and Small G.W. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction Semin. Nucl. Med. 38 4 2008 251 261 10.1053/j.semnuclmed.2008.02.006 18514081
65. Spence J.S.; Carmack P.S.; Gunst R.F.; Schucany W.R.; Woodward W.A.; and Haley R.W. Using a white matter reference to remove the dependency of global signal on experimental conditions in SPECT analyses Neuroimage 32 1 2006 49 53 10.1016/j.neuroimage.2006.03.025 16651010
66. Sperling R.A.; Aisen P.S.; Beckett L.A.; Bennett D.A.; Craft S.; and Fagan A.M. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 3 2011 280 292 10.1016/j.jalz.2011.03.003 21514248
67. Tapiola T.; Alafuzoff I.; Herukka S.K.; Parkkinen L.; Hartikainen P.; and Soininen H. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch. Neurol. 66 3 2009 382 389 10.1001/archneurol.2008.596 19273758
68. Teune L.K.; Bartels A.L.; de Jong B.M.; Willemsen A.T.; Eshuis S.A.; and de Vries J.J. Typical cerebral metabolic patterns in neurodegenerative brain diseases Mov. Disord. 25 14 2010 2395 2404 10.1002/mds.23291 20669302
69. Thiele F.; Young S.; Buchert R.; and Wenzel F. Voxel-based classification of FDG PET in dementia using inter-scanner normalization Neuroimage 77 2013 62 69 10.1016/j.neuroimage.2013.03.031 23541799
70. Ward A.; Arrighi H.M.; Michels S.; and Cedarbaum J.M. Mild cognitive impairment: disparity of incidence and prevalence estimates Alzheimers Dement. 8 1 2012 14 21 10.1016/j.jalz.2011.01.002 22265588
71. Warrington E.K.; and James M. The Visual Object and Space Perception Battery 1991 Thames Valley Test Company, St. Edmunds Bury, UK
72. Whitwell J.L.; Dickson D.W.; Murray M.E.; Weigand S.D.; Tosakulwong N.; and Senjem M.L. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study Lancet Neurol. 11 10 2012 868 877 10.1016/S1474-4422(12)70200-4 22951070
73. Yaffe K.; Petersen R.C.; Lindquist K.; Kramer J.; and Miller B. Subtype of mild cognitive impairment and progression to dementia and death Dement. Geriatr. Cogn. Disord. 22 4 2006 312 319 10.1159/000095427 16940725